Lv3
220 积分 2025-03-13 加入
Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma
1个月前
已完结
Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
1个月前
已完结
Eribulin for patients with metastatic extramammary Paget disease: Study protocol for a single‐arm phase II trial
1个月前
已完结
69P Efficacy and safety of eribulin in liposarcoma and leiomyosarcoma: A systematic review and meta-analysis
1个月前
已完结
Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study
1个月前
已完结
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
1个月前
已完结
Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
1个月前
已完结
Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis
1个月前
已完结
Post-marketing safety study of Eribulin: a real-world, retrospective pharmacovigilance study leveraging the FAERS database
1个月前
已完结
皖公网安备34019202002308
